Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Volume
35
Pagination
48 - +
DOI
10.1200/JCO.2015.66.3468
Journal
JOURNAL OF CLINICAL ONCOLOGY
Issue
ISSN
0732-183X